There can be few topics upon which it is as difficult to obtain accurate statistical information as it is upon the incidence of abortion in human pregnancy. It has been suggested that at least onethird of all pregnancies in this country end in abortion, and this is probably a conservative estimate. The incidence of congenital malformation is again a matter for speculation but the incidence of severe deformity recognizable at birth seems to be at least 2 %. It is most important to bear these figures in mind when considering the effects of drugs upon the early embryo, since it is all too easy to assume that there is a causal relationship between drug administration and malformation where none in fact exists. Theoretically, drugs may either improve the situation of an embryo, leave it unaffected, deform it or kill it. In some cases, the administration of a chemical substance which does not affect development unfavourably will nevertheless be followed by the birth of a deformed child. It moreover seems quite likely that drugs either exist now or will do so in future which preserve the life of an embryo otherwise doomed to die, so that it is born alive but deformed. Finally a drug which reduces the chances of survival of the embryo may also cause malformation in babies which might otherwise be born healthy and normal. Such a drug might have the additional effect of causing the abortion of an embryo which might otherwise, have survived to be born as a live deformed baby.-Since the majority of potential parents would regard abortion as preferable to the birth of a live severely deformed baby, the problem of the administration of drugs to women of child-bearing age will always be most complex and difficult.
The problem is indeed more intricate than this, for the concepts outlined above require an assumption which some, though not all, teratologists would support, that the death of an embryo in utero represents the more severe effect of a teratogenic agent whose administration would in lower dosage have resulted in the birth of a live baby with a congenital malformation. This assumption is clearly justified in the case of certain agents, such as X-rays, provided administration is restricted to a certain critical period of pregnancy.
It is not, however, always possible to establish a clear-cut relationship between embryotoxic and embryopathic activity, and the subtleties of interaction between the teratogenic and lethal dosages of a drug inevitably complicate the issue.
One further source of difficulty arises from the fact that we cannot as yet do more than propose mechanisms by which a teratogenic agent may exert its deleterious effect. In view of the current interest in the chemistry of the genetic apparatus it is tempting to rush straight to the cellular level and to suggest that thalidomide, for example, replaces some part of the DNA molecule and exerts its noxious action in a direct and simple fashion. This may well turn out to be so, but a variety of other possibilities must be taken into account. Table 1 shows the main ways in which theoretically the embryo may be affected by a drug administered to the mother. Clearly it 'is not enough merely to identify a teratogenic agent as present in large quantities in a fcetus to establish that its action on the fretus is direct, although the converse is obviously true, for if the substance or one of its metabolites is not found in the foetus, there must be some intermediate step in teratogenesis involving the mother, the placenta or both. By injecting pregnant mice with a large dose of vitamin A on a day critical for the development of the palate, we have produced litters in which some of the young have cleft palate and some are normal. Although both the deformed young and those that have escaped deformity contain more Table I Possible sites of primary action of genetic and environmental factors
The maternal tissues (circulating blood, liver, kidney, brain, heart, uterus, ductless glands) Modes of action: (a) Reduction in oxygen-carrying capacity of blood (b) Alteration in the level of blood glucose (c) Reduced availability of essential vitamins, hormones, amino acids and trace elements
The placenta Modes of action: (a) Interference with passage of oxygen, glucose or other vital substances across the placenta (b) Interference with blood supply ofplacenta
The embryo Modes of action: (a) Direct effect on the cells in the structure which is to be deformed (b) Action on embryonic liver (c) Action on fwtal heart and circulation (d) Action on embryonic endocrine system vitamin A than the offspring of untreated dams, the concentration of vitamin A is no greater in the affected embryos than in their normal siblings. These findings may be interpreted in a variety of ways. It might be said that with more refined techniques for vitamin A estimation than at present exist it would be possible to find differences in vitamin level. The differences in response to the teratogen as between litter-mates may be attributed to subsidiary factors, such as position in the uterus or minor differences in genetic constitution. One can postulate that the prime site of teratogenic activity is in the mother or placenta, and that the effect of hypervitaminosis-A is mediated by reduction in the oxygen-carrying capacity of the maternal blood or alteration in the level of glucose in the blood of mother and fcetus. Suppose, however, that our experiments had shown that there was more vitamin A in the deformed embryos than in their normal siblings. Surely it would then have been just as necessary to consider the possibility that the quantity of vitamin A in the embryo was immaterial and that the site of primary activity was elsewhere in the mother or placenta.
A drug administered before the embedding of the blastocyst may kill the embryo, but does not deform it. This suggests one of two things: the existence of the placenta is essential to teratogenic activity, or the pre-implantation blastocyst is not sufficiently mature to react to a noxious stimulus except by means of an 'all-or-nothing' response. It is important here to realize that as St Hilaire (1821) put it, 'La monstruosite n'est pas une extravagance, elle est faite selon les regles'. The rules for making even a monster seem not to be clear before embedding has taken place. In a monster, and certainly in any malformation which is compatible with life, deformity is an expression of a limited amount of damage to a small part of the animal; until a germ of differentiation exists in the various systems of the animal, only the life of the embryo is at stake. Perhaps the major question to be answered in mammalian teratology is: Do the teratogenic agents which have been identified act in much the same way, or is there a variety of modes of action to each of which at least a few agents owe their toxicity? There is a remarkable disparity between the long catalogue of agents that are known to produce malformations in experimental animals and the brief list of known environmental causes of human malformation. Nevertheless, the thalidomide disaster has shown that chemical substances can cause human malformations, and there is some point, therefore, in considering and evaluating the agents known to produce malformations in laboratory animals and in attempting to equate the findings of animal experiments with the tetiology of human malformations.
The study of experimental mammalian teratology dates from the discovery made thirty years ago by the American veterinarian Hale (1933) , that piglets born to sows maintained on a diet deficient in vitamin A were born without eyeballs. Since this original discovery, a large number of agents have been identified, in many cases by accident, which are capable of producing deformities in the young of laboratory mammals.
These agents are listed in Tables 2-4. Table 2 gives substances with which the animal body is Table 2 Chemical substances taking part in normal metabolism and their antagonists, whose administration or deprivation may cause fetal abnormality in experimental animals familiar and their antagonists. Vitamins and hormones and their antagonists are perhaps particularly relevant to man because nutritional disturbances and hormonal imbalance may frequently accompany human pregnancy. All the agents in Table 2 could exert their effects by direct action on the cells in the structure which is to be deformed. What little we know about the factors determining the levels of vitamins and hormones in the embryo suggests that, during the critical period for the development of the major structures in the body, the embryo is entirely under maternal control as far as these levels are concerned. The embryo is consequently wide open to agents which are free to change the levels of vitamins and hormones in the embryonic tissues in the direction of either deficiency or excess. Table 3 includes a wide range of substances not concerned in normal mammalian metabolism. If the action of each of these substances were better understood, it could presumably be classified under one of the sub-headings of Table 2 . It has been suggested, for example, that thalidomide and tetracycline owe their teratogenic activity to interference with the metabolic role of various members of the B group of vitamins. Table 3 Substances not concerned in normal mammalian metabolism whose administration may cause fietal abnormality in experimental animals Alkylating agents: nitrogen mustard, &c. Chelating agents: ethylenediaminetetracetic acid, &c. Antibiotics: penicillin, streptomycin, tetracycline, actinomycin D Azo dyes: trypan blue, &c. Antisera: rabbit anti-rat kidney serum (in rat only) Miscellaneous: thalidomide, salicylates, nicotine, caffeine, urethane, lead nitrate, phenyl mercuric acetate, aminobenzene derivatives Table 4 Physical agents which may cause fetal abnormality X-radiation Decompression, hypoxia, anoxia, carbon dioxide excess, carbon monoxide poisoning Hypothermia, hyperthermia Amniotic sac puncture Noise
The physical agents listed in Table 4 may have the same kind of harmful effect on embryonic development as do chemical substances. Noise presumably requires the mother as an intermediary; amniotic sac puncture and, as Wilson (1954) has ingeniously shown, X-radiation appear to act directly on the embryo.
Aspects of teratogenesis which have so far received little attention are the interactions of teratogenic agents with one another and the 33 possibility of sensitizing the embryo to, or protecting it from, the noxious effect of a given agent. It is not surprising that these aspects should have been neglected for they require experimentation which is expensive both in time and in money, and the study of mammalian teratology is still in its infancy. We have investigated the factors which may be used to modify the effects of hypervitaminosis-A in rodents, using cleft palate and exencephaly as yardsticks. We have found that cortisone (Millen & Woollam 1957 , Woollam & Millen 1957 and methylthiouracil sensitize the embryo to the teratogenic effects of vitamin A, and that the embryo is protected against these effects either by insulin, thyroxine or members of the B group ofvitamins (Woollam & Millen 1960) . We also found that insulin opposed the sensitizing effect of cortisone (Millen & Woollam 1958) . We believe that the ability to modify teratogenic effects is important not only because of possible future therapeutic applications but because of the bearing that it has on one of the most difficult aspects of experimental teratogenesis.
Whilst the type and incidence of deformity produced by a given teratogenic agent depend more on the time at which it is administered than on the level of dosage or any other single factor, there are nevertheless, as between teratogenic agents, wide differences in the spectra of malformations produced. The effect of thalidomide in the human is a classic example of this phenomenon. The three environmental factors known to produce deformed babiesrubella, thalidomide and aminopterinproduce very different malformations. To some extent this could obviously be the result of timing. Thalidomide was not apparently taken by expectant mothers entirely without reference to the period of pregnancy, but in many cases specifically to alleviate morning sickness. The critical period for anencephaly, the 16th to 24th day, is, for example, rather before that at which morning sickness might be expected to occur and anencephaly has not been reported following thalidomide. However, the critical period for the development of phocomelia is from the 27th to the 44th day, just at the time when morning sickness is most prevalent. Rubella on the other hand seems to produce a syndrome the critical period for which is later, possibly because when it operates earlier it kills the embryo. Nevertheless, after taking into account the importance of timing and also the fact that deformities other than phocomelia have been reported following the ingestion of thalidomide, there does seem to be a predilection on the part of this drug to interfere with the development of the long bones. Between the two extremes of seeing on the one hand the activity of all teratogenic agents as manifesting itself through a final common path and, on the other, of regarding each teratogenic agent as having its own idiosyncratic pattern of effect on the enzymatic processes of the cell, we would hold an intermediate view, inclining more to the former. Our experience suggests that there are probably a small number ofpathwaysbywhich malformations are produced. We do not, indeed, totally exclude the possibility that there may be a single final cause as, for example, interference with carbohydrate metabolism or production of temporary anoxia. We would see, these final pathways as responsible for the broad pattern of malformations, while the detailed variations would be attributable to a number of genetic and environmental factors. Of these factors unquestionably the most important is the maternal and feetal genotype with all the implications of interand intra-species differences in response to teratogenic agents which this implies. We would, nevertheless, regard the environmental factors as more important in regulating the response of the embryo to teratogenic agents than might those who have approached the subject from genetics and experimental embryology where the great advances have been made in the study of submammalian forms. Only during the short period between fertilization and the embedding of the blastocyst does the situation of the mammalian embryo resemble that of the embryo of lower forms. It is worth repeating that it is precisely during this period that teratogenic agents do not work as such: they kill, but they do not maim the embryo. In the development of insects, nonviviparous fishes, amphibians and birds, from the study of which so many of our basic genetic and embryological concepts have been formulated, the maternal contribution after fertilization is restricted to the provision of, at most, physical protection and warmth. In the mammal where the foetus receives so much more directly from the motherthe minerals and amino acids needed for growth, the glucose and oxygen needed to maintain the existing tissuesit is obvious that the mother as a whole, her age, size, physical fitness, previous reproductive history, nutritional standdards and hormonal levels may be of vital importance in serving to modify the response of the embryo to a teratogenic agent.
From the concepts of teratogenic activity outlined above we have reached the following conclusions on the testing of new drugs for teratogenic activity on the mammalian embryo. For comparisons between tests carried out in different institutions or in the same institution at different times, a rigorous protocol must be adopted. It is not only necessary to use animals of as nearly as possible identical heredity for experimental and control groups, it is also obligatory to use animals of standard size, weight and previous reproductive performance, fed, watered an.d exposed to sunlight and warmth at a predetermined level. In addition, there should be an agreed time of day for the administration of drugs to be tested. Even with the strictest adherence to this procedure, we believe that no drug should finally be regarded as safe, or condemned as noxious, for the human embryo, on the basis of animal experiments alone. We must stress, however, that experimental mammaLian teratology itself is yet hardly in its infancy, even though the blastocyst was embedded as it were by Hale as long as thirty years ago. So far we have seen the contributions made by a few observers working in a variety of disciplines at schools scattered widely over the globe on a subject, the lack of financial support for which indicated its insignificance in practical affairs. Now that the vast resources of the drug industry and of private and nationalized medicine are to be poured into research in this field, our tentative conclusions may relate in some way to the fundamental principles that must shortly be revealed. Here we have for once a problem in the solution ofwhich pure and applied science will both equally rejoice and equally benefit, for the drug industry will hardly be able to learn how to test its products adequately without finding out in the process much that embryologists have been wanting to know for a long time.
